title: 15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer.
abstract: We investigated the tumor suppressor activity and regulatory mechanism of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in gastric cancer; 15-PGDH expression was lost in 70.1% of malignant human gastric tissues, but was preserved in normal and metaplastic gastritis. KATO III and SNU-719 cells were transfected with pcDNA3.1-empty vector or an expression vector encoding wild-type 15-PGDH. In TUNEL assays apoptotic cell numbers were increased in KATO-PGDH-WT cells compared with control. We found that EGFR and ERK1/2 inhibitors clearly increased the expression of 15-PGDH in KATO III cells. Our findings demonstrate both downregulation and a tumor suppressor activity of 15-PGDH in gastric cancer.
authors.affiliation: Asan Digestive Disease Research Institute and Asan Institute for Life Sciences, Seoul, Korea.
authors.forename: Ho June
authors.initials: HJ
authors.lastname: Song
authors.forename: Seung-Jae
authors.initials: SJ
authors.lastname: Myung
authors.forename: In-Wha
authors.initials: IW
authors.lastname: Kim
authors.forename: Jin-Yong
authors.initials: JY
authors.lastname: Jeong
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Park
authors.forename: Sun Mi
authors.initials: SM
authors.lastname: Lee
authors.forename: Won Hee
authors.initials: WH
authors.lastname: Nam
authors.forename: Yeon-Mi
authors.initials: YM
authors.lastname: Ryu
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Fink
authors.forename: Dong-Hoon
authors.initials: DH
authors.lastname: Yang
authors.forename: Hwoon-Yong
authors.initials: HY
authors.lastname: Jung
authors.forename: Jin-Ho
authors.initials: JH
authors.lastname: Kim
mesh_terms: D000236:Adenoma / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D017209:Apoptosis; D002277:Carcinoma / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D015232:Dinoprostone / Q000378:metabolism; D015536:Down-Regulation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D005756:Gastritis / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000235:genetics / Q000378:metabolism*; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D008679:Metaplasia; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D011230:Precancerous Conditions / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D013274:Stomach Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D013997:Time Factors; D014162:Transfection; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; D025521:Tumor Suppressor Proteins; D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase; C512478:EGFR protein, human; D066246:ErbB Receptors; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D015232:Dinoprostone